irAEs
[용어속성] Term
Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world study
암 환자 치료에서 PD-1 억제제의 사용에 대한 COVID-19 백신 접종의 영향 : 실제 연구
Observational Study
[키워드] Adverse
adverse event
adverse events
age
All participants
Analysis
Aside
BBIBP-CorV
Cancer
Chinese hospital
Clinical efficacy
Common Terminology Criteria
Comorbidities
Comorbidity
conducted
conjunction
COVID-19
COVID-19 vaccination
COVID-19 vaccine
criteria
defined
determine
disease
disease control
Efficacy
Efficacy and safety
eligible patient
enrolled
evaluate
event
female
first dose
Frequency
functional
Gender
GRADE
Grade 1
grade 3
greater
immune
Immunotherapy
Impact
implication
inhibitor
intestinal tract
irAE
irAEs
less
liver
lung
median age
median interval
metastatic cancer
Mild
Most patient
Most patients
multicenter observational study
no significant difference
no significant differences
observational study
Participants
Patient
Patients with cancer
PD-1
performance status
Propensity score
receive
receiving
recruited
reduce
reduced
reported
response
response rate
screened
selected
Side effect
significant differences
Solid
statistically
status
subgroup
subgroups
the median
Therapies
therapy
Treatment
Tumor
vaccination
Vaccine
was used
were used
[DOI] 10.1136/jitc-2021-004157 PMC 바로가기 [Article Type] Observational Study
[DOI] 10.1136/jitc-2021-004157 PMC 바로가기 [Article Type] Observational Study
PET/CT variants and pitfalls in malignant melanoma
악성 흑색종의 PET/CT 변이체 및 함정
Review
[키워드] adverse event
Algorithms
Cancer
Community
confirmation
COVID 19
COVID19
described
detect
diagnostic
digital PET
disease
False-positive
FDG
focus
immune activation
Immune checkpoint inhibitor
Immune checkpoint inhibitors
Immunotherapy
IMPROVE
include
increasingly
indication
indications
induce
Interpretation
irAEs
kinase inhibitors
learning curve
lesions
limitations
Malignant melanoma
Melanoma
pandemic
patients
pet
PET technology
PET/CT
Pitfalls, variants
protocol
released
staging
Therapies
tyrosine
tyrosine kinase inhibitor
tyrosine kinase inhibitors
variant
variants
[DOI] 10.1186/s40644-021-00440-4 PMC 바로가기 [Article Type] Review
[DOI] 10.1186/s40644-021-00440-4 PMC 바로가기 [Article Type] Review
Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm
항-CD28 항체(TGN1412) 유발 사이토카인 폭풍 후 면역 재구성 및 임상 회복
Clinical Trial
[키워드] adverse event
adverse events
antibody
asymptomatic patients
autoantibody
Cancer immunotherapy
CD28
CD4
CD8
cells
clinical recovery
clinical trial
cognitive
Cognitive deficits
Concentration
consequence
COVID-19
cytokine
Cytokine dysregulation
cytokine release
Cytokine release syndrome
Cytokine storm
Cytokines
Day
declined
defined
dendritic cell
dendritic cells
Depression
described
diagnosed
dry gangrene
dysregulation
elevated
Follow-up
Gastrointestinal
healthy volunteer
IgE
immune
immune dysregulation
Immune monitoring
Immune-related adverse events (irAEs)
immunopathology
Immunotherapy
infections
initial
irAEs
irritability
memory
Mild-to-moderate
mucosal
naïve
neutropenia
observation
one patient
over
Patient
problem
problems
pruritus
Psychological
raynaud s phenomenon
required
serum cytokine
serum cytokines
subset
suffered
Symptom
systemic symptoms
T-cell
T-cells
T-regulatory cell
T-regulatory cells
targets
TGN1412.
Treatment
undetectable
[DOI] 10.1007/s00262-020-02725-2 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1007/s00262-020-02725-2 PMC 바로가기 [Article Type] Clinical Trial